0.1524
price down icon21.52%   -0.0576
after-market Dopo l'orario di chiusura: .15 -0.0024 -1.57%
loading
Precedente Chiudi:
$0.21
Aprire:
$0.145
Volume 24 ore:
11,517
Relative Volume:
66.00
Capitalizzazione di mercato:
$N/A
Reddito:
-
Utile/perdita netta:
$-16.08M
Rapporto P/E:
-0.00443
EPS:
-34.43
Flusso di cassa netto:
$-11.54M
1 W Prestazione:
-21.52%
1M Prestazione:
-80.61%
6M Prestazione:
-86.27%
1 anno Prestazione:
-97.18%
Intervallo 1D:
Value
$0.145
$0.154
Intervallo di 1 settimana:
Value
$0.145
$0.154
Portata 52W:
Value
$0.145
$0.154

Bio Path Holdings Inc Stock (BPTH) Company Profile

Name
Nome
Bio Path Holdings Inc
Name
Telefono
-
Name
Indirizzo
-
Name
Dipendente
0
Name
Cinguettio
Name
Prossima data di guadagno
Name
Ultimi documenti SEC
Name
BPTH's Discussions on Twitter

Confronta BPTH con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
BPTH
Bio Path Holdings Inc
0.1524 0 0 -16.08M -11.54M -34.43
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
462.13 117.32B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
558.87 58.89B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
401.80 51.14B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
673.80 41.02B 3.05B 1.28B -614.78M 19.58
Biotechnology icon
ONC
Beone Medicines Ltd Adr
299.01 32.59B 3.81B -644.79M -669.77M -6.24

Bio Path Holdings Inc Stock (BPTH) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2021-03-11 Iniziato ROTH Capital Buy
2017-11-13 Reiterato H.C. Wainwright Buy
2016-08-10 Reiterato Maxim Group Buy
2016-04-18 Iniziato Rodman & Renshaw Buy
2014-06-02 Ripresa Maxim Group Buy
2014-05-09 Iniziato Maxim Group Buy
Mostra tutto

Bio Path Holdings Inc Borsa (BPTH) Ultime notizie

pulisher
Aug 02, 2025

Bio-Path Holdings, Inc. (NASDAQ:BPTH) Short Interest Update - Defense World

Aug 02, 2025
pulisher
Jul 31, 2025

Tevogen Bio Holdings Inc. stock trend outlook and recovery pathFree Long Hold Safe Return Strategy - Newser

Jul 31, 2025
pulisher
Jul 29, 2025

Adicet Bio Inc. stock trend outlook and recovery pathLow Risk Picks for Daily Trading Released - metal.it

Jul 29, 2025
pulisher
Jul 28, 2025

Cutaneous T-Cell Lymphoma Pipeline Outlook Report 2025: Key 25+ Companies and Breakthrough Therapies Shaping the Future Landscape - The Globe and Mail

Jul 28, 2025
pulisher
Jul 28, 2025

TOPAZ REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS DEMONSTRATING STRONG ROYALTY AND INFRASTRUCTURE GROWTH - The Globe and Mail

Jul 28, 2025
pulisher
Jul 28, 2025

Cutaneous T-Cell Lymphoma Pipeline Outlook Report 2025: Key 25+ Companies And Breakthrough Therapies Shaping The Future Landscape - Menafn

Jul 28, 2025
pulisher
Jul 25, 2025

Antisense & RNAi Therapeutics Market Outlook 2025-2033: - GlobeNewswire

Jul 25, 2025
pulisher
Jul 25, 2025

The Zacks Analyst Blog Highlights Meta Platforms, Alphabet, Microsoft and Tesla - The Globe and Mail

Jul 25, 2025
pulisher
Jul 25, 2025

Antisense & RNAi Therapeutics Market Outlook 2025-2033: Advancements in Drug Delivery Propel Growth with Revenues Forecast to Reach $3.3 Billion by 2033 - Yahoo Finance

Jul 25, 2025
pulisher
Jul 24, 2025

Tucows Announces Timing for Q2 2025 Financial Results News Release and Management Commentary - The Globe and Mail

Jul 24, 2025
pulisher
Jul 24, 2025

Meta Platforms Is Helping Power This 6%-Yielding Dividend Stock's Continued Growth - The Globe and Mail

Jul 24, 2025
pulisher
Jul 23, 2025

Google's AI push pays off with solid second quarter, but doubts about company's future persist - The Globe and Mail

Jul 23, 2025
pulisher
Jul 23, 2025

Tevogen Bio Holdings Inc. Stock Analysis and ForecastFree Daily Trading Room Entry - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

What analysts say about Tevogen Bio Holdings Inc. stockFree Predictions - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Cutaneous T-cell Lymphoma Market Anticipates Impressive - GlobeNewswire

Jul 22, 2025
pulisher
Jul 21, 2025

Cutaneous T-cell Lymphoma Market Anticipates Impressive Growth Trajectory at a CAGR of 7.1% During the Study Period (2020–2034) | DelveInsight - GlobeNewswire

Jul 21, 2025
pulisher
Jul 21, 2025

Cutaneous T-cell lymphoma Clinical Trials 2025: EMA, PDMA, FDA - openPR.com

Jul 21, 2025
pulisher
Jul 21, 2025

Cutaneous T-cell lymphoma Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, Mechanism of Action, Route of Administration, and Companies by DelveInsight - Barchart.com

Jul 21, 2025
pulisher
Jul 21, 2025

Freeport-McMoRan to Post Q2 Earnings: What's in Store for the Stock? - The Globe and Mail

Jul 21, 2025
pulisher
Jul 20, 2025

What drives Tevogen Bio Holdings Inc. stock priceFree Stock Selection - printweek.in

Jul 20, 2025
pulisher
Jul 18, 2025

Carvana Is Up 100x Since the 2022 Lows. Could This Stock Be Next? - The Globe and Mail

Jul 18, 2025
pulisher
Jul 17, 2025

Mullen Announces Plan to Change Company’s Name to Bollinger Innovations, Inc. and NASDAQ Approval for New Symbol — BINI - The Globe and Mail

Jul 17, 2025
pulisher
Jul 16, 2025

Antisense Oligonucleotide Therapeutics Pipeline Appears - openPR.com

Jul 16, 2025
pulisher
Jul 15, 2025

Antisense Oligonucleotide Therapeutics Pipeline Appears Robust With 15+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - Barchart.com

Jul 15, 2025
pulisher
Jul 15, 2025

Menin Inhibitors Market Forecasts Signal Strong Uptake of Menin Inhibitors in Hematologic Oncology Across the 7MM During the Forecast Period (2020-2034) | DelveInsight - PR Newswire UK

Jul 15, 2025
pulisher
Jul 15, 2025

Antisense Oligonucleotide Therapeutics Pipeline Appears Robust With 15+ Key Pharma Companies Actively Working In The Therapeutics Segment Delveinsight - Menafn

Jul 15, 2025
pulisher
Jul 14, 2025

Oligonucleotides Competitive Landscape 2025: 320+ Therapies - openPR.com

Jul 14, 2025
pulisher
Jul 14, 2025

Waldenstrom Macroglobulinemia Market Sees Surging Demand - GlobeNewswire

Jul 14, 2025
pulisher
Jul 14, 2025

Waldenstrom Macroglobulinemia Market Sees Surging Demand Across the 7MM Amid BTK Inhibitor Advancements | DelveInsight - Business Upturn

Jul 14, 2025
pulisher
Jul 14, 2025

Massive $888M Deal: Biotech Firm Makes Historic Pivot to Become Largest US Public HYPE Token Holder - Stock Titan

Jul 14, 2025
pulisher
Jul 14, 2025

Where Will Arista Networks Be in 5 Years? - The Globe and Mail

Jul 14, 2025
pulisher
Jul 08, 2025

30 Billion Reasons to Buy Oracle Stock Like There's No Tomorrow - The Globe and Mail

Jul 08, 2025
pulisher
Jul 07, 2025

Fantastic News for CoreWeave Shareholders - The Globe and Mail

Jul 07, 2025
pulisher
Jul 03, 2025

Delisting of Securities from The Nasdaq Stock Market - The Manila Times

Jul 03, 2025
pulisher
Jun 24, 2025

Bio-Path Holdings announces executive resignations and operational pause - Investing.com

Jun 24, 2025
pulisher
Jun 24, 2025

Bio-Path Holdings Faces Leadership Changes and Operational Pause, Considers Strategies Amid Limited Capital - AInvest

Jun 24, 2025
pulisher
Jun 20, 2025

Bio-Path Holdings Faces Leadership Changes and Operational Pause - TipRanks

Jun 20, 2025
pulisher
Jun 17, 2025

Cutaneous T Cell Lymphoma Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - Barchart.com

Jun 17, 2025
pulisher
Jun 17, 2025

Oligonucleotides Clinical Trial Pipeline Analysis Demonstrates 280+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - SINA HONG KONG LIMITED

Jun 17, 2025
pulisher
Jun 13, 2025

Life Sciences Investor Forum: Now Available for Online Viewing - The Manila Times

Jun 13, 2025
pulisher
Jun 12, 2025

GitLab (NASDAQ:GTLB) Given New $60.00 Price Target at Wells Fargo & Company - Defense World

Jun 12, 2025
pulisher
Jun 12, 2025

GRI Bio’s (GRI) Buy Rating Reaffirmed at HC Wainwright - Defense World

Jun 12, 2025
pulisher
Jun 12, 2025

Short Interest in Bitcoin Depot Inc. (NASDAQ:BTMWW) Expands By 5,350.0% - Defense World

Jun 12, 2025
pulisher
Jun 12, 2025

GitLab (NASDAQ:GTLB) Price Target Cut to $52.00 by Analysts at JPMorgan Chase & Co. - Defense World

Jun 12, 2025
pulisher
Jun 12, 2025

Bio-Path Holdings, Inc. (NASDAQ:BPTH) Short Interest Up 870.6% in May - Defense World

Jun 12, 2025
pulisher
Jun 12, 2025

Two Sigma Investments LP Cuts Position in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) - Defense World

Jun 12, 2025
pulisher
Jun 12, 2025

Two Sigma Investments LP Reduces Stock Holdings in Industrial Logistics Properties Trust (NASDAQ:ILPT) - Defense World

Jun 12, 2025
pulisher
Jun 12, 2025

Two Sigma Investments LP Makes New $273,000 Investment in ORIX Co. (NYSE:IX) - Defense World

Jun 12, 2025
pulisher
Jun 12, 2025

MetaVia to Present at Virtual Investor Forum June 12, 2025. - AInvest

Jun 12, 2025
pulisher
Jun 11, 2025

Life Sciences Investor Forum Agenda Announced for June 11th-12th - GlobeNewswire

Jun 11, 2025
pulisher
Jun 09, 2025

Bio-Path Holdings to Present at Life Sciences Virtual Investor F - GuruFocus

Jun 09, 2025

Bio Path Holdings Inc Azioni (BPTH) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$75.59
price up icon 0.93%
$37.11
price up icon 0.84%
$108.69
price up icon 1.31%
$27.07
price up icon 2.65%
$107.34
price down icon 0.15%
biotechnology ONC
$299.01
price down icon 0.70%
Capitalizzazione:     |  Volume (24 ore):